BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 33555447)

  • 1. Medulloblastoma: clinicopathological parameters, risk stratification, and survival analysis of immunohistochemically validated molecular subgroups.
    Eid AM; Heabah NAE
    J Egypt Natl Canc Inst; 2021 Feb; 33(1):6. PubMed ID: 33555447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicomorphological and molecular analysis of medulloblastoma and association with survival: A single tertiary care center experience.
    Badiger S; Gudipati A; Uppin M; Konatam ML; Yeramneni VK; Bhattacharjee S; Saradhi MV; Patnaik S; Irukulla M
    J Cancer Res Ther; 2023 Jan; 19(Suppl 2):S592-S602. PubMed ID: 38384024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical Surrogates for Molecular Stratification in Medulloblastoma.
    Chinnam D; Saraswati A; Jogunoori S; Verma A; Kiran T; Salunke P; Gupta N; Kumar N; Madan R; Radotra BD; Gupta K
    Appl Immunohistochem Mol Morphol; 2023 Sep; 31(8):561-568. PubMed ID: 37471625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathological characteristics, molecular subgrouping, and expression of miR-379/miR-656 cluster (C14MC) in adult medulloblastomas.
    Kaur K; Kakkar A; Kumar A; Purkait S; Mallick S; Suri V; Sharma MC; Julka PK; Gupta D; Suri A; Sarkar C
    J Neurooncol; 2016 Dec; 130(3):423-430. PubMed ID: 27576698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemical and nanoString-Based Subgrouping of Clinical Medulloblastoma Samples.
    D'Arcy CE; Nobre LF; Arnaldo A; Ramaswamy V; Taylor MD; Naz-Hazrati L; Hawkins CE
    J Neuropathol Exp Neurol; 2020 Apr; 79(4):437-447. PubMed ID: 32053195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medulloblastoma in China: clinicopathologic analyses of SHH, WNT, and non-SHH/WNT molecular subgroups reveal different therapeutic responses to adjuvant chemotherapy.
    Zhang ZY; Xu J; Ren Y; Li KK; Ng HK; Mao Y; Zhong P; Yao Y; Zhou LF
    PLoS One; 2014; 9(6):e99490. PubMed ID: 24932704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups.
    Ellison DW; Dalton J; Kocak M; Nicholson SL; Fraga C; Neale G; Kenney AM; Brat DJ; Perry A; Yong WH; Taylor RE; Bailey S; Clifford SC; Gilbertson RJ
    Acta Neuropathol; 2011 Mar; 121(3):381-96. PubMed ID: 21267586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of low and very high-risk patients with non-WNT/non-SHH medulloblastoma by improved clinico-molecular stratification of the HIT2000 and I-HIT-MED cohorts.
    Mynarek M; Obrecht D; Sill M; Sturm D; Kloth-Stachnau K; Selt F; Ecker J; von Hoff K; Juhnke BO; Goschzik T; Pietsch T; Bockmayr M; Kool M; von Deimling A; Witt O; Schüller U; Benesch M; Gerber NU; Sahm F; Jones DTW; Korshunov A; Pfister SM; Rutkowski S; Milde T
    Acta Neuropathol; 2023 Jan; 145(1):97-112. PubMed ID: 36459208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular subgroups of adult medulloblastoma: a long-term single-institution study.
    Zhao F; Ohgaki H; Xu L; Giangaspero F; Li C; Li P; Yang Z; Wang B; Wang X; Wang Z; Ai L; Zhang J; Luo L; Liu P
    Neuro Oncol; 2016 Jul; 18(7):982-90. PubMed ID: 27106407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Approach to molecular subgrouping of medulloblastomas: Comparison of NanoString nCounter assay versus combination of immunohistochemistry and fluorescence in-situ hybridization in resource constrained centres.
    Kaur K; Jha P; Pathak P; Suri V; Sharma MC; Garg A; Suri A; Sarkar C
    J Neurooncol; 2019 Jul; 143(3):393-403. PubMed ID: 31104222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medulloblastoma: Clinicopathological Correlates of SHH, WNT, and Non-WNT/SHH Molecular Subgroups Analysis and Prognostic Significance: Mono-Institutional Series.
    Hasbay B; Kayaselcuk F; Suner HI; Sarialioglu F
    Turk Neurosurg; 2022; 32(4):595-602. PubMed ID: 34751426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular Stratification of Medulloblastoma: Clinical Outcomes and Therapeutic Interventions.
    Sursal T; Ronecker JS; Dicpinigaitis AJ; Mohan AL; Tobias ME; Gandhi CD; Jhanwar-Uniyal M
    Anticancer Res; 2022 May; 42(5):2225-2239. PubMed ID: 35489737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrating Molecular Subclassification of Medulloblastomas into Routine Clinical Practice: A Simplified Approach.
    Kaur K; Kakkar A; Kumar A; Mallick S; Julka PK; Gupta D; Suri A; Suri V; Sharma MC; Sarkar C
    Brain Pathol; 2016 May; 26(3):334-43. PubMed ID: 26222673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medulloblastoma in Adults: Cytogenetic Phenotypes Identify Prognostic Subgroups.
    Goschzik T; Zur Muehlen A; Doerner E; Waha A; Friedrich C; Hau P; Pietsch T
    J Neuropathol Exp Neurol; 2021 Apr; 80(5):419-430. PubMed ID: 33870422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular Classification of Medulloblastoma.
    Kijima N; Kanemura Y
    Neurol Med Chir (Tokyo); 2016 Nov; 56(11):687-697. PubMed ID: 27238212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid diagnosis of medulloblastoma molecular subgroups.
    Schwalbe EC; Lindsey JC; Straughton D; Hogg TL; Cole M; Megahed H; Ryan SL; Lusher ME; Taylor MD; Gilbertson RJ; Ellison DW; Bailey S; Clifford SC
    Clin Cancer Res; 2011 Apr; 17(7):1883-94. PubMed ID: 21325292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk Stratification of Childhood Medulloblastoma Using Integrated Diagnosis: Discrepancies with Clinical Risk Stratification.
    Cho HW; Lee H; Ju HY; Yoo KH; Koo HH; Lim DH; Sung KW; Shin HJ; Suh YL; Lee JW
    J Korean Med Sci; 2022 Feb; 37(7):e59. PubMed ID: 35191235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simplified Molecular Subtyping of Medulloblastoma for Reduced Cost and Improved Turnaround Time.
    Shuangshoti S; Tadadontip P; Techavichit P; Thorner PS; Shuangshoti S; Teerapakpinyo C
    Appl Immunohistochem Mol Morphol; 2020 Aug; 28(7):538-543. PubMed ID: 31343993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exclusive Hyperfractionated Radiation Therapy and Reduced Boost Volume for Standard-Risk Medulloblastoma: Pooled Analysis of the 2 French Multicentric Studies MSFOP98 and MSFOP 2007 and Correlation With Molecular Subgroups.
    Carrie C; Kieffer V; Figarella-Branger D; Masliah-Planchon J; Bolle S; Bernier V; Laprie A; Supiot S; Leseur J; Habrand JL; Alapetite C; Kerr C; Dufour C; Claude L; Chapet S; Huchet A; Bondiau PY; Escande A; Truc G; Nguyen TD; Pasteuris C; Vigneron C; Muracciole X; Bourdeaut F; Appay R; Dubray B; Colin C; Ferlay C; Dussart S; Chabaud S; Padovani L; ;
    Int J Radiat Oncol Biol Phys; 2020 Dec; 108(5):1204-1217. PubMed ID: 32768563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mir-449a, a potential diagnostic biomarker for WNT group of medulloblastoma.
    Li Y; Jiang T; Shao L; Liu Y; Zheng C; Zhong Y; Zhang J; Chang Q
    J Neurooncol; 2016 Sep; 129(3):423-431. PubMed ID: 27406588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.